Lv51
970 积分 2022-11-17 加入
Abstract 9318: The Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Ebronucimab in Healthy Volunteers: Result From a Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation Study
1个月前
已关闭
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
1个月前
已完结
Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Current status and future perspectives of FGF21 analogues in clinical trials
2个月前
已完结
Proprotein convertase subtilisin/kexin type 9 targets megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome
3个月前
已完结
Inhibition of an immunometabolic axis of mTORC1 activation extends mammalian healthspan
3个月前
已完结
Abstract 2365: Disrupting IL-11/IL-11R signaling by an efficacious anti-IL-11 antibody 9MW3811 enhances T cell tumor infiltration and synergizes with anti-PD-1 therapies in vivo
3个月前
已关闭
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
4个月前
已完结
Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity
7个月前
已完结
皖公网安备34019202002308
